280 related articles for article (PubMed ID: 31042025)
1. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling.
Muratcioglu S; Aydin C; Odabasi E; Ozdemir ES; Firat-Karalar EN; Jang H; Tsai CJ; Nussinov R; Kavakli IH; Gursoy A; Keskin O
J Mol Biol; 2020 Feb; 432(4):1199-1215. PubMed ID: 31931009
[TBL] [Abstract][Full Text] [Related]
3. 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
Nastasă C; Tamaian R; Oniga O; Tiperciuc B
Medicina (Kaunas); 2019 Mar; 55(4):. PubMed ID: 30935124
[No Abstract] [Full Text] [Related]
4. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
[TBL] [Abstract][Full Text] [Related]
5. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors.
Kazi A; Ranjan A; Kumar M V V; Agianian B; Garcia Chavez M; Vudatha V; Wang R; Vangipurapu R; Chen L; Kennedy P; Subramanian K; Quirke JCK; Beato F; Underwood PW; Fleming JB; Trevino J; Hergenrother PJ; Gavathiotis E; Sebti SM
Cancer Res Commun; 2023 Dec; 3(12):2623-2639. PubMed ID: 38051103
[TBL] [Abstract][Full Text] [Related]
6. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology.
Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto JI; Kamaura M; Cho N; Tani A
Biochem Biophys Res Commun; 2017 Mar; 484(3):605-611. PubMed ID: 28153726
[TBL] [Abstract][Full Text] [Related]
7. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
[TBL] [Abstract][Full Text] [Related]
8. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; García-Echeverría C; Weissleder R; Mahmood U; Cantley LC; Wong KK
Nat Med; 2008 Dec; 14(12):1351-6. PubMed ID: 19029981
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract][Full Text] [Related]
10. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
11. Molecular Basis for Allosteric Inhibition of GTP-Bound H-Ras Protein by a Small-Molecule Compound Carrying a Naphthalene Ring.
Matsumoto S; Hiraga T; Hayashi Y; Yoshikawa Y; Tsuda C; Araki M; Neya M; Shima F; Kataoka T
Biochemistry; 2018 Sep; 57(36):5350-5358. PubMed ID: 30141910
[TBL] [Abstract][Full Text] [Related]
12. Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase.
Kakarala KK; Jamil K
Curr Comput Aided Drug Des; 2022; 18(7):506-518. PubMed ID: 36321226
[TBL] [Abstract][Full Text] [Related]
13. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
[TBL] [Abstract][Full Text] [Related]
14. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
15. Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate.
Gupta AK; Wang X; Pagba CV; Prakash P; Sarkar-Banerjee S; Putkey J; Gorfe AA
Chem Biol Drug Des; 2019 Aug; 94(2):1441-1456. PubMed ID: 30903639
[TBL] [Abstract][Full Text] [Related]
16. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
17. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
[TBL] [Abstract][Full Text] [Related]
18. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
Diaz-Flores E; Goldschmidt H; Depeille P; Ng V; Akutagawa J; Krisman K; Crone M; Burgess MR; Williams O; Houseman B; Shokat K; Sampath D; Bollag G; Roose JP; Braun BS; Shannon K
Sci Signal; 2013 Dec; 6(304):ra105. PubMed ID: 24300897
[TBL] [Abstract][Full Text] [Related]
19. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Ostrem JM; Peters U; Sos ML; Wells JA; Shokat KM
Nature; 2013 Nov; 503(7477):548-51. PubMed ID: 24256730
[TBL] [Abstract][Full Text] [Related]
20. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
